This, after the Medicines Control Council (MCC) announced on Tuesday (29/07/03) that it rejects the findings of a re-monitoring report ordered in March last year into the conduct of the Uganda HIVNET-012 clinical study. It was this trial that formed the basis on which the drug was registered for the prevention of HIV from mother to child in South Africa, in 2001. Khopotso Bodibe reports.

To obtain the audio file please contact the Editor.